Market Cap | 1.92M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -980.79k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | - |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -85.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | 5.00% | 52W High Chg | -100.00% |
Recommedations | - | Quick Ratio | 0.04 | Shares Outstanding | 96.05M | 52W Low Chg | - |
Insider Own | 2.52% | ROA | -115.51% | Shares Float | 99.88M | Beta | 97.46 |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00010 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 2,518 | Target Price | - |
Oper. Margin | - | Earnings Date | - | Volume | 7,500 | Change | 0.00% |
CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.